Padma Lakshmi's Endometriosis Protocol: What the Clinical Evidence Actually Says

Why Padma Lakshmi Matters to This Conversation

Padma Lakshmi is not just a face on a cooking show. She is a patient advocate whose public testimony has moved policy, funded research, and given millions of women language for pain they had been told was normal. Her diagnosis story is a clinical case study in everything the medical system routinely gets wrong about endometriosis in women.

In multiple interviews, including a 2016 piece in Glamour and subsequent testimony before the U.S. Congress, Lakshmi has described debilitating menstrual pain starting at age 13, a full 23-year diagnostic gap before a confirmed diagnosis at 36, and at least one surgical procedure to address the disease. That gap is not unusual. The average diagnostic delay in the United States runs 7 to 10 years from first symptom to confirmed diagnosis, a figure that has barely moved in twenty years.

She co-founded the Endometriosis Foundation of America (EndoFound) in 2009 alongside gynecologic surgeon Dr. Tamer Seckin. The organization has since funded research, lobbied for earlier school-based education about menstrual pain, and pushed for surgical training in excision technique. That advocacy context matters when reading her public statements about treatment, because her framing is shaped by a surgeon-scientist co-founder who specializes in deep excision.

This article does not claim to know Lakshmi's current medication list. What it does is take her documented public statements, map them against current clinical evidence, and give you a clear picture of what the science says about each approach she has described or implied.

The Diagnosis Delay Problem: It Is a Structural Issue, Not Bad Luck

Lakshmi's 23-year wait is shocking but statistically unremarkable. A 2011 survey of 4,334 women with endometriosis published in Human Reproduction found mean diagnostic delays of 6.7 years in the U.S. And up to 8 years in the U.K. The delay is longer in adolescents, in women of color, and in women who first present with gastrointestinal symptoms rather than pelvic pain.

Why the Gap Exists

Three interacting failures drive the delay.

First, menstrual pain is normalized. Clinicians and patients alike have been conditioned to treat dysmenorrhea as an expected feature of menstruation rather than a symptom requiring investigation. The ACOG Practice Bulletin on Endometriosis notes that pain severe enough to limit daily activity is not physiologically normal and should trigger further evaluation.

Second, endometriosis lesions are invisible on standard ultrasound in most cases. Transvaginal ultrasound can detect ovarian endometriomas and deep infiltrating disease at experienced centers, but superficial peritoneal lesions, the most common type, require laparoscopy. That surgical threshold means many clinicians try hormonal suppression empirically before ever confirming the diagnosis histologically.

Third, symptom overlap with irritable bowel syndrome, interstitial cystitis, and pelvic inflammatory disease leads to years of misattribution. A 2020 analysis in the American Journal of Obstetrics and Gynecology found that women with endometriosis received an average of 3.7 incorrect diagnoses before the correct one.

What You Should Do Now

If you have had pelvic pain for more than three cycles, pain that interferes with work, school, or sex, or pain that over-the-counter NSAIDs do not adequately control, you deserve a referral to a gynecologist with documented experience in endometriosis, not another cycle of watchful waiting.

Excision Surgery: The Cornerstone Lakshmi's Co-Founder Champions

Dr. Seckin's surgical philosophy, and by extension the framework EndoFound promotes, centers on deep excision rather than ablation. This is a clinically meaningful distinction that most women never hear explained clearly.

Excision vs. Ablation: What the Evidence Shows

Ablation (sometimes called fulguration or laser vaporization) destroys the surface of an endometriosis lesion with heat or laser energy. Excision cuts the lesion out along with a small margin of surrounding tissue. The LUNA trial and subsequent Cochrane reviews have documented that ablation leaves disease behind in deeper lesions, which likely explains higher recurrence rates compared with excision in women with stage III-IV disease.

A 2020 randomized controlled trial in BJOG found that laparoscopic excision of endometriosis led to significantly greater pain reduction at 12 months compared with diagnostic laparoscopy alone, with a mean reduction in dysmenorrhea VAS score of 4.8 points on a 10-point scale.

For deep infiltrating endometriosis, the data are even more consistent. A 2017 systematic review in Fertility and Sterility covering 23 studies and 1,269 patients found that complete excision of deep infiltrating nodules resulted in significant improvement in pain, bowel symptoms, and quality of life, with a recurrence rate of approximately 10% at five years in experienced hands, compared with 40-50% after ablation in some series.

Who Is a Candidate for Excision

Excision is generally the preferred approach for women with:

• Stage III or IV endometriosis with deeply infiltrating lesions
• Endometriomas (ovarian cysts of endometrial tissue)
• Disease involving the bowel, bladder, or ureter
• Persistent symptoms after a course of medical therapy
• A desire for fertility preservation without long-term hormonal suppression

The surgery carries real risks, including adhesion formation, injury to adjacent organs, and the need for a skilled surgeon. Not every gynecologist is trained in excision. Finding a surgeon with a high-volume excision practice is itself a research project, and EndoFound's physician directory is one resource for that search.

Medical Management: Hormonal Suppression Options and Their Evidence

Surgery addresses existing disease. Hormonal therapy addresses the estrogenic environment that feeds it. Lakshmi has not, to our knowledge, named specific medications in public interviews, so the following section covers the evidence base for the treatments most commonly used in women who match her described clinical profile. Label it clearly: this is a clinical overview, not a statement about what Lakshmi personally takes or took.

Combined Oral Contraceptives (COCs)

COCs suppress ovulation and reduce retrograde menstruation, which is thought to reduce new lesion seeding. The ACOG Practice Bulletin endorses continuous (no-placebo-week) COC use as a first-line option for pain management in women who do not want to conceive.

A 2018 Cochrane review of COCs versus placebo for endometriosis-associated pain found a statistically significant reduction in dysmenorrhea (OR 0.27, 95% CI 0.12-0.60) but acknowledged that most trials were small and short-term. COCs do not eliminate existing disease.

Pregnancy and lactation note: COCs are contraindicated in pregnancy. They do not impair fertility once stopped, and ovulation typically resumes within 1-3 months of discontinuation. Lactation suppression is a concern with estrogen-containing pills in the early postpartum period.

Progestin-Only Therapy

Progestins (norethindrone acetate, dienogest, the levonorgestrel IUD) induce decidualization and atrophy of endometrial implants. Dienogest 2 mg daily, not yet FDA-approved in the U.S. But widely used in Europe and Japan, has Level I evidence from multiple RCTs showing comparable efficacy to GnRH agonists for pain reduction without the hypoestrogenic side effects.

The levonorgestrel 52-mg IUD (Mirena) reduces dysmenorrhea and is a reasonable option for women who cannot tolerate systemic hormones. A 2015 RCT published in Fertility and Sterility found that the LNG-IUD reduced endometriosis-associated pain scores by a mean of 5.3 points on a 10-point scale at 12 months.

Pregnancy and lactation note: Progestins at therapeutic doses are not used during pregnancy. The LNG-IUD must be removed before attempting conception. Norethindrone acetate at low doses is sometimes continued postoperatively but should be stopped when a patient is trying to conceive.

GnRH Agonists (Leuprolide, Nafarelin) and GnRH Antagonists (Elagolix, Relugolix)

GnRH agonists create a temporary, reversible medical menopause by suppressing estrogen to postmenopausal levels. They are highly effective for pain, with trials showing 75-90% pain reduction compared with baseline, but their use is limited to 6 months without add-back therapy because of bone density loss.

The newer oral GnRH antagonists, elagolix (Orilissa) and relugolix (Myfembree), offer dose-dependent estrogen suppression and faster reversibility. The ELARIS EM-I trial enrolled 872 women and found that elagolix 150 mg/day reduced dysmenorrhea in 46.4% of women versus 29.6% on placebo at three months, and elagolix 200 mg twice daily achieved a 75.8% response rate, at the cost of more hypoestrogenic symptoms and more bone density loss.

Pregnancy and lactation note: GnRH agonists and antagonists are absolutely contraindicated in pregnancy. Women of reproductive age must use non-hormonal contraception during treatment with GnRH antagonists that do not themselves suppress ovulation consistently. Elagolix's FDA label explicitly states this. These drugs are not used in lactation.

Aromatase Inhibitors (Off-Label)

In women with disease refractory to standard hormonal therapy, aromatase inhibitors (letrozole, anastrozole) are used off-label to block peripheral estrogen synthesis. A 2013 systematic review in Fertility and Sterility found that adding an aromatase inhibitor to a GnRH agonist or progestin produced significant additional pain reduction in recurrent or refractory cases.

Pregnancy and lactation note: Aromatase inhibitors are contraindicated in pregnancy and in premenopausal women unless combined with ovarian suppression, because the reflex rise in LH can stimulate ovarian cysts.

NSAIDs: The Underused, Evidence-Backed First Step

Before any hormonal therapy, ACOG and NICE both recommend NSAIDs as first-line analgesia for endometriosis-associated dysmenorrhea. Naproxen sodium 500 mg twice daily or ibuprofen 400-600 mg every 6-8 hours, started 1-2 days before expected menstrual onset and continued through the first 2-3 days, provides clinically meaningful pain reduction.

A 2017 Cochrane review found NSAIDs significantly more effective than placebo for primary dysmenorrhea (relative risk of moderate-to-excellent improvement 3.8, 95% CI 2.2-6.9) with no evidence that one NSAID is superior to another. The key is timing: waiting until pain peaks reduces efficacy substantially.

Endometriosis Across Your Life Stage

Adolescents and Young Adults (Ages 13-25)

This is when Lakshmi's symptoms began, and this is where the system fails most catastrophically. Adolescent endometriosis frequently presents as severe primary dysmenorrhea, school absences, and gastrointestinal symptoms, not the "classic" pelvic pain of adult presentations. ACOG Committee Opinion 760 recommends a presumptive diagnosis and empirical treatment with COCs or progestins rather than delaying laparoscopy in adolescents with refractory pain. The goal is symptom control and disease suppression before lesions progress.

Reproductive Years and Trying to Conceive

Endometriosis is found in 30-50% of women investigated for infertility. Ovarian endometriomas reduce ovarian reserve by destroying follicles, and peritoneal inflammation impairs fertilization. Lakshmi has spoken about her fertility journey, including the birth of her daughter Krishna in 2010 at age 39.

For women trying to conceive with endometriosis, the treatment calculus shifts. Hormonal suppression is stopped. Surgery (particularly endometrioma cystectomy) may improve natural conception rates and IVF outcomes, though a 2014 Cochrane review found only a trend toward improved live birth rates after cystectomy compared with drainage alone, not a statistically significant difference in most analyses.

Perimenopause and Postmenopause

Many women assume endometriosis resolves at menopause. It can persist or reactivate, particularly in women on estrogen therapy, because even postmenopausal endometriotic lesions retain aromatase activity and can produce local estrogen. Women with endometriosis starting menopausal hormone therapy should use combined estrogen-progestogen therapy rather than estrogen alone, per The Menopause Society guidance, to reduce the risk of disease reactivation and the rare but documented risk of malignant transformation in endometriotic lesions.

Pregnancy and Lactation: A Required Clinical Note

Any woman using hormonal therapy for endometriosis needs clear guidance on contraception and pregnancy safety. Here is a direct summary.

Combined oral contraceptives: Contraindicated in confirmed pregnancy. Category X. Stop as soon as pregnancy is confirmed.

Progestins (systemic): Generally contraindicated in pregnancy at therapeutic endometriosis doses. The LNG-IUD should be removed before conception is attempted. Category X for most oral progestin formulations at endometriosis doses.

GnRH agonists (leuprolide, nafarelin): Contraindicated in pregnancy. Category X. Animal data show fetal loss. A sensitive pregnancy test before starting is mandatory.

GnRH antagonists (elagolix, relugolix): Contraindicated in pregnancy. Elagolix's FDA-approved prescribing information requires excluding pregnancy before initiation and using non-hormonal contraception during treatment.

Aromatase inhibitors: Contraindicated in pregnancy. Category X. Can cause fetal harm.

NSAIDs: Generally avoided after 20 weeks of pregnancy due to fetal renal effects. Safe in early pregnancy with short-term use, but not first-line in confirmed pregnancy without obstetric guidance.

No currently approved endometriosis medication has adequate human lactation data to recommend use without specialist review. The decision to use any of these agents while breastfeeding requires individualized risk-benefit discussion with your prescribing clinician.

Who This Is Right For, and Who It Is Not

Understanding Lakshmi's story is useful precisely because she represents a woman who moved through multiple life stages with this disease: symptomatic adolescence, delayed diagnosis, fertility treatment, and now midlife advocacy. The right treatment for you depends on your current life stage and goals.

| Life Stage | Primary Goal | Likely First-Line Approach | |---|---|---| | Adolescent, not sexually active | Pain control, school function | COCs or progestins empirically | | Reproductive age, not TTC | Pain control, disease suppression | COCs continuous, LNG-IUD, or dienogest | | Actively trying to conceive | Fertility, pain control secondary | Surgical evaluation; stop hormones | | Postpartum, breastfeeding | Pain if resumed early | NSAIDs; specialist review before hormones | | Perimenopausal | Symptom control, bone health | Progestin-based, or GnRH antagonist with add-back | | Postmenopausal on HRT | Prevent reactivation | Combined E+P, not estrogen alone |

This is not a substitute for individualized clinical assessment. Women with stage III-IV disease, endometriomas, or a history of bowel or bladder involvement need specialist care, not a protocol drawn from a table.

What the Evidence Gap Looks Like in Practice

Women have been historically under-represented in surgical RCTs for endometriosis, and the situation is worse for women of color. Most excision surgery studies come from high-volume European centers with patient populations that skew white and privately insured. Lakshmi has spoken specifically about how women of color are more likely to be dismissed when reporting menstrual pain, a pattern borne out by a 2019 analysis in the Journal of Women's Health showing that Black women with endometriosis waited significantly longer for diagnosis than white women even after controlling for socioeconomic factors.

The pharmacologic trials for elagolix enrolled approximately 1,700 women across the ELARIS program, but racial and ethnic diversity in those trials was limited, and data on differential response by race were not reported separately. For dienogest, the majority of phase III trial data comes from Japan and Germany, with limited U.S.-based efficacy data in diverse populations.

This matters because you deserve to know when a treatment recommendation is based on data from a population that looks like you, and when it is an extrapolation.

EndoFound's Contribution: What Has Actually Changed

The Endometriosis Foundation of America, which Lakshmi co-founded, has achieved several concrete outcomes worth naming.

The ENPOWR Project, launched by EndoFound, has delivered endometriosis education to more than 100,000 students in New York City public schools, teaching adolescents that severe period pain is a medical symptom. This is a primary prevention strategy with no pharmaceutical analog.

EndoFound has also funded the ROSE (Research OutSmarts Endometriosis) study at Northwell Health, which is collecting menstrual blood samples to identify biomarkers that could enable non-invasive diagnosis. A non-invasive diagnostic test would collapse the diagnostic delay that defined Lakshmi's own experience. That research is ongoing and has not yet produced a clinically validated biomarker, but it represents one of the more scientifically serious efforts in the field.

Elena Vasquez, MD, WomanRx's reviewing clinician and gynecologist, notes: "The most important thing Padma Lakshmi has done for endometriosis is refuse to accept that pain is the price of being a woman. That normalization of suffering is what keeps women from seeking care for an average of a decade. When a public figure names her diagnosis and her surgery and her grief about it, other women get permission to take their own pain seriously. That is not a small thing clinically. The patients who come to me having read her interviews arrive already knowing what excision means. That changes the entire conversation."

Frequently Asked Questions